What type of study is this?

This is a RCT study (also classified as: Human Clinical Trial, Pre-Registered Trial).

August 21, 2025The International Journal of Cardiovascular ImagingOpen Access

Impact of alirocumab on neoatherosclerosis formation and vessel healing after drug-eluting stent implantation in patients with acute myocardial infarction: a substudy of the PACMAN-AMI trial

View Full Paper

Ask AI

Bookmark

No significant impact of alirocumab on neoatherosclerosis was observed in AMI patients treated with drug-eluting stents.
The frequency of neoatherosclerosis was similar between alirocumab (4.2%) and placebo (9.4%) groups, with a P-value of 0.25.
Assessment involved a randomized, double-blind trial comparing alirocumab to placebo added to high-intensity statin therapy.
Findings imply a need for larger studies to verify the vascular healing effects noted with alirocumab treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial reveals no significant difference in neoatherosclerosis rates between alirocumab and placebo in AMI patients, suggesting further research is needed.

Cite This Study

Kakizaki et al. (2025) studied this question.

synapsesocial.com/papers/68a6fb925502675167ba8ef1 https://doi.org/10.1007/s10554-025-03472-0

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial reveals no significant difference in neoatherosclerosis rates between alirocumab and placebo in AMI patients, suggesting further research is needed.

Impact of alirocumab on neoatherosclerosis formation and vessel healing after drug-eluting stent implantation in patients with acute myocardial infarction: a substudy of the PACMAN-AMI trial

Key Points

Discussion

Implication

Cite This Study

Impact of alirocumab on neoatherosclerosis formation and vessel healing after drug-eluting stent implantation in patients with acute myocardial infarction: a substudy of the PACMAN-AMI trial

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider